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EDITORIAL
Taking  care  of the  caretakers  to enhance  antiretroviral
adherence in HIV-infected  children  and
adolescents,
Cuidando  dos  cuidadores  para  melhorar  a  adesão  antirretroviral  em
crianc¸as  e  adolescentes  infectados  com  o  HIV
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iThe  article  by  Cruz  et  al.,  ‘‘Viral  suppression  and  adher-
ence among  HIV-infected  children  and  adolescents  on
antiretroviral therapy:  results  of  a  multicenter  study,’’1 pub-
lished in  this  journal  reports  important  results  regarding
adherence to  combined  antiretroviral  treatments  from  a
large multicenter  trial  in  perinatal  human  immunodeﬁ-
ciency virus  (HIV)-infected  children  and  adolescents  with
HIV in  ﬁve  geographically-distinct  reference  centers  of
Brazil. Although  major  advances  have  been  made  in  the
diagnosis, treatment,  and  access  to  antiviral  drugs  for  chil-
dren and  adolescents  with  HIV,  the  desired  outcome  of  a
healthy and  prolonged  life  is  limited  by  the  ability  of  the
child/adolescent and  the  caregiver  to  consistently  adhere  to
the daily  need  to  take  multiple  antiretroviral  medications.2Chronic  administration  of  medication  is  a  considerable  chal-
lenge in  most  populations,  and  especially  so  in  adolescents.3
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0021-7557/© 2014 Sociedade Brasileira de Pediatria. Published by ElseviAs  reported  by  Cruz  et  al.,  despite  collection  of  data
rom questionnaires  with  adherence  rates  of  92.6%  of  chil-
ren (caregivers  information)  and  77.2%  of  adolescents,  only
7%  of  children  and  28/57  (49%)  of  adolescents  had  docu-
ented HIV  RNA  viral  loads  below  50  cp/mL.  Adherence  to
edications is  critical  to  assure  persistent  suppression  of
IV to  undetectable  levels,  which  allows  for  the  potential
econstitution of  CD4  T-cells  and  immune  competence,  pre-
enting the  rapid  development  of  antiviral  resistance  and
ltimate virological  failure.  There  are  limited  opportuni-
ies for  new  effective  antiviral  regimens,  as  observed  in
his population,  where  63%  of  subjects  were  on  or  beyond
heir second  regimen.  Our  goals  should  be  directed  towards
mproving medication  adherence  with  the  ﬁrst  regimen,
iven to  children  and  adolescents  as  early  as  possible  follow-
ng diagnosis  in  order  to  maximize  the  long-term  outcome
nd reduce  the  potential  for  development  of  viral  drug
esistance.
Numerous studies  have  used  different  methods  to  assess
dherence in  HIV-infected  children  and  adults  with  varying
esults. In  pediatric  populations,  adherence  questionnaires
bout cART-missed  doses  are  used  most  frequently  as  in
dults. Other  methods  include  records  of  pharmacy  visits;
edication diaries;  pill  counts  by  study  personnel  and
y electronic  devices  such  as  Medication  Event  Monitor-
ng System  (MEMS)  (AARDEX  Ltd,  Union  City,  CA,  USA)
er Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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analysis of cases followed from 1983 to 2002 in different regions34  
aps;  and  therapeutic  drug  monitoring.4--6 The  article  by
ruz et  al.  found  that  the  questionnaires  about  adher-
nce were  unreliable,  since  the  caretakers  and  adolescent
ubjects were  more  optimistic  about  the  consistency  of
dherence than  what  was  evidenced  by  the  percentage  of
hildren/adolescents with  documentation  of  controlled  viral
eplication. Several  key  points  are  worthy  of  reiteration;  if
nstituted, they  could  improve  the  overall  outcome  of  HIV-
nfected children  and  adolescents.
The  authors  observed  that  careful  monitoring  of  phar-
acy records  are  key  to  assure  adherence,  since  those  who
eturned approximately  monthly  for  new  prescriptions  were
igniﬁcantly  more  likely  to  remain  virologically  suppressed
han those  who  came  less  frequently.  There  ought  to  be  a
onthly ﬂag  sent  to  clinicians  and  care  partners  if  prescrip-
ions are  not  picked  up.  Other  innovative  solutions,  such  as
ome delivery  of  medications,  could  be  used  if  necessary.
harmacy reports  can  provide  immediately  useful  informa-
ion that  can  be  easily  incorporated  into  routine  care  as  a
onitoring tool.7
Another  key  component  was  the  ﬁnding  that  health;  use
f drugs  and  alcohol;  and  mental,  cognitive,  and  quality
f life  assessments  of  the  caregiver  were  very  important
n predicting  adherence  and  in  identifying  areas  to  provide
ssistance. The  authors  used  the  Alcohol,  Smoking,  and  Sub-
tance Involvement  Screening  Test  (ASSIST)  as  a  screening
ool for  caretakers;  this  practice  has  been  proven  success-
ul in  other  studies  and  is  recommended  by  the  World  Health
rganization (WHO)  for  adults  with  HIV,  since  management
f substance  abuse  has  been  associated  with  commitment
o cART  treatment  28.
As  expected,  a  negative  association  between  moder-
te/heavy alcohol  consumption  and  viral  suppression  has
een reported  in  the  literature.8 Likewise,  increased  anx-
ety scores  of  caretakers  have  been  associated  with  poor
dherence. In  such  cases,  focused  interventions  to  help  the
aretakers could  then  be  instituted.  The  incorporation  of  a
creening instrument  for  drug  use  and  quality  of  life  among
aregivers may  contribute  to  strategies  aiming  to  improve
dherence in  the  pediatric  population.
During  this  study,  from  2009  to  2011,  the  majority  of  chil-
ren and  adolescents  in  follow-up  were  diagnosed  late,  at
 median  of  9.5  years  after  the  onset  of  symptoms,  and
3% were  diagnosed  after  the  onset  of  acquired  immunode-
ciency syndrome  (AIDS),  which  may  reﬂect  on  the  ability  to
chieve sustained  viral  suppression,  as  well  as  family  atti-
udes about  the  necessity  of  daily  ARV  treatment.  The  best
dherence rates  were  observed  in  infants  or  children  diag-
osed early  as  a  result  of  follow-up  of  a  HIV-seropositive
other or  family  member.
Advances  in  the  integrated  care  of  HIV-infected  pregnant
others and  HIV-exposed  children,  availability  of  early  diag-
osis, better  access  to  antiviral  medications,  and  changes
n ARV  guidelines  have  greatly  improved  the  initiation  of
ARV in  pediatric  and  adolescent  populations  in  Brazil  and
lsewhere.9
Due  to  a  major  reduction  in  early  mortality  and  morbid-
ty with  initiation  of  early  combined  antiviral  treatment  in
nfants, treatment  of  all  HIV-infected  infants  diagnosed  less
han one  yearis  now  recommended.10--12
Improving  the  ability  to  sustain  HIV  viral  suppression  is  a
ontinuing challenge,  not  only  to  reduce  the  emergence  ofBryson  Y
iral  drug  resistance  and  to  improve  the  quality  of  life,  but
lso to  achieve  the  potential  future  goal  of  HIV  remission.
A  large  clinical  trial  of  prevention  of  mother-to-child  HIV
ransmission conducted  in  Brazil,  South  Africa,  Argentina,
nd the  United  States  enrolled  high  risk  infants  within
8 hours  of  age,  born  to  HIV-infected  mothers  who  did  not
eceive prenatal  treatment,  and  showed  that  infants  who
eceived two  or  three  ARVs  prophylactically,  compared  to
ingle dose  Zidovudine,  had  50%  reduction  of  transmission
t the  time  of  birth.13 This  study  observed  that  the  iden-
iﬁcation of  HIV-positive  pregnant  mothers  at  the  time  of
elivery and  their  high-risk  HIV-exposed  neonates  is  feasible
n Brazil  and  in  other  middle-income  countries,  such  as  South
frica; infants  can  be  started  on  ARV  very  early  as  part  of
 comprehensive  program  of  prevention  of  mother-to-child
IV transmission.
The recent  report  of  HIV  remission  in  an  infant  who
as infected  with  HIV  in  utero  and  received  early  (31  hours
f age)  triple  combination  treatment,  who  has  been  off
ntiretroviral treatment  for  three  years  without  evidence  of
IV rebound,  has  spurred  further  studies  of  early  ARV  treat-
ent for  high-risk  HIV  infants  and  is  expected  to  enroll  in
razil.14,15
In  addition,  recent  studies  in  HIV-infected  adolescents
ave shown  that  early  combination  treatment  at  less  than
 months  of  age  and  long-term,  consistentlu  tight  control
f viral  replication  in  perinatally  HIV-infected  patients  lead
o reduction  and  continual  decay  of  HIV  viral  reservoirs.16--18
mproved  point-of-care  rapid  diagnosis  in  infants  and  more
requent monitoring  of  HIV  viral  load  in  order  to  assure  ade-
uate viral  suppression  are  still  needed.
Starting  combination  ARV  treatment  early  and  assuring
he best  possible  adherence  during  early  years,  with  the
oal of  reducing  HIV  viral  reservoirs  and  preserving  immune
unction, and  even  preparing  these  children  for  strategies
argeting HIV  remission,  is  critical  for  their  long-term  out-
ome of  these  children.
These new  goals  make  the  ﬁndings  of  the  article  by
ruz et  al.  even  more  important,  in  order  to  direct  efforts
o enhance  adherence  in  this  vulnerable  population,  who
epend on  caretakers  and  medical  infrastructure  to  ensure
hat medications  are  available  and  delivered  over  many
ears. We  need  to  help  take  care  of  the  caretakers  of  HIV
nfected children  and  adolescents.
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